Human psychopharmacology最新文献

Plasma levels of interleukin-8 and response to paroxetine in patients with major depressive disorder. 重度抑郁症患者血浆白细胞介素-8水平及对帕罗西汀的反应

IF 1.7

Human psychopharmacology Pub Date : 2022-11-01 Epub Date: 2022-10-04 DOI: 10.1002/hup.2855

Xuan Guan, Zai-Quan Dong, Yan-Ni Hao, Xiao-Ling Shen, Qing-Lian Xie, Jian-Min Chen

{"title":"Plasma levels of interleukin-8 and response to paroxetine in patients with major depressive disorder.","authors":"Xuan Guan, Zai-Quan Dong, Yan-Ni Hao, Xiao-Ling Shen, Qing-Lian Xie, Jian-Min Chen","doi":"10.1002/hup.2855","DOIUrl":"https://doi.org/10.1002/hup.2855","url":null,"abstract":"Objectives: Immune dysregulation plays a key role in major depressive disorder (MDD). However, little is known about the complicated involvement of various interleukins in MDD. This study was performed to investigate the correlation between plasma interleukin-8 (IL-8) levels and treatment outcome of paroxetine (a selective serotonin reuptake inhibitor) in patients with MDD.Methods: A total of 115 hospitalized patients (36 males and 79 females), aged from 18 to 72 years, were enrolled. Plasma levels of IL-8 were measured before treatment initiation (baseline) and at 8 weeks after oral paroxetine treatment. Efficacy of paroxetine was evaluated by use of the Hamilton Depression Rating Scale (HAMD-17). Baseline IL-8 levels were compared between responders and non-responders to paroxetine treatment.Results: Plasma IL-8 levels decreased significantly after an 8-week antidepressant treatment in responders, in association with a dramatic decrease in HAMD-17 scores. In non-responders, plasma IL-8 levels did not change significantly at 8 weeks after antidepressant treatment. Baseline plasma IL-8 levels were found to be significantly lower in responders than in non-responders, showing a correlation between IL-8 and antidepressant response to paroxetine.Conclusions: These results indicate that plasma IL-8 levels were related to treatment outcome of paroxetine, and therefore suggest that IL-8 could be a promising predicator of treatment response in individual patients with MDD.","PeriodicalId":520641,"journal":{"name":"Human psychopharmacology","volume":" ","pages":"e2855"},"PeriodicalIF":1.7,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33487663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Facilitated extinction of conditioned fear responses by delta 9-tetrahyrdrocannabidol in humans: a pilot study. 9-四氢大麻酚促进人类条件恐惧反应的消除:一项初步研究。

IF 1.7

Human psychopharmacology Pub Date : 2022-11-01 Epub Date: 2022-08-19 DOI: 10.1002/hup.2853

Herman A Diggs, Norka E Rabinovich, David G Gilbert

{"title":"Facilitated extinction of conditioned fear responses by delta 9-tetrahyrdrocannabidol in humans: a pilot study.","authors":"Herman A Diggs, Norka E Rabinovich, David G Gilbert","doi":"10.1002/hup.2853","DOIUrl":"https://doi.org/10.1002/hup.2853","url":null,"abstract":"Objective: We sought to determine whether acute delta 9-tetrahyrdrocannabidol (THC) administration would facilitate fear extinction in young occasional cannabis users, given that animal models indicate THC facilitates extinction learning, and recent studies indicate THC administration may also enhance threat memory extinction in humans.Methods: On each of the 2 days, 24+ hour THC-deprived participants were conditioned to fear visual stimuli in a delay conditioning and extinction paradigm. Both CS+ and CS- were faces of negative emotional valence, with the CS+ paired with mild electric shock. Throughout both conditioning and extinction paradigms, EEG was measured to quantify event-related potentials for these learning processes. Following conditioning, individuals, in a randomized and counter-balanced order, smoked either an active THC cigarette (26.25 mg/2.7% THC) or a placebo marijuana cigarette (0.002% THC) on 1 day and the opposite cigarette on the second day. After smoking, CS+ and CS- were presented without shock, resulting in extinction of conditioned fear.Results: Relative to placebo, THC facilitated extinction of the conditioned response to the CS+, as reflected by reductions in late positive potential amplitude during extinction learning.Conclusions: The results indicate that acute THC administration may facilitate extinction of the conditioned fear response in humans.","PeriodicalId":520641,"journal":{"name":"Human psychopharmacology","volume":" ","pages":"e2853"},"PeriodicalIF":1.7,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40624754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Inflammatory markers at baseline correlate with subsequent clinical response to quetiapine in patients with bipolar disorder. 基线炎症标志物与双相情感障碍患者随后对喹硫平的临床反应相关。

IF 1.7

Human psychopharmacology Pub Date : 2022-11-01 Epub Date: 2022-09-07 DOI: 10.1002/hup.2854

Marco Ferrari, Marco Godio, Stefano Martini, Camilla Callegari, Marco Cosentino, Franca Marino

引用次数: 4

Association between the angiotensin-converting enzyme gene insertion/deletion polymorphism and first-episode patients with schizophrenia in a Chinese Han population. 血管紧张素转换酶基因插入/缺失多态性与中国汉族首发精神分裂症患者的关系

IF 1.7

Human psychopharmacology Pub Date : 2014-05-01 Epub Date: 2014-03-11 DOI: 10.1002/hup.2396

Li Hui, Jing Qin Wu, Xuan Zhang, Jie Lv, Wei Li Du, Chang Gui Kou, Ya Qin Yu, Meng Han Lv, Da Chun Chen, Xiang Yang Zhang

{"title":"Association between the angiotensin-converting enzyme gene insertion/deletion polymorphism and first-episode patients with schizophrenia in a Chinese Han population.","authors":"Li Hui, Jing Qin Wu, Xuan Zhang, Jie Lv, Wei Li Du, Chang Gui Kou, Ya Qin Yu, Meng Han Lv, Da Chun Chen, Xiang Yang Zhang","doi":"10.1002/hup.2396","DOIUrl":"https://doi.org/10.1002/hup.2396","url":null,"abstract":"Background: Angiotensin-converting enzyme (ACE), a key enzyme of the renin-angiotensin system, can modulate dopamine turnover in the midbrain. Previous studies have revealed an association between ACE gene insertion/deletion (I/D) polymorphism and chronic schizophrenia, yet results are conflicting.Objective: The primary objective of this study was to examine whether the ACE gene I/D polymorphism is associated with first-episode patients with schizophrenia (FEP) in a Chinese Han population.Methods: The presence of the polymorphism was determined in 220 FEP and 538 healthy controls using a case-control design. We assessed the psychopathology in 212 FEP using the Positive and Negative Syndrome Scale (PANSS).Results: The allelic and genotypic frequencies of the ACE gene I/D polymorphism did not significantly differ between FEP and healthy controls (both p>0.05). However, the negative PANSS symptom was significantly higher in FEP with the D/D genotype than those with I/D and I/I genotypes (all p<0.05) even after Bonferroni corrections (all p<0.05). Furthermore, the D allele of the ACE gene was associated with higher negative PANSS symptom score in FEP.Conclusions: Our results indicated that even though the ACE gene I/D polymorphism did not associate with FEP, it may play a role in susceptibility to the negative PANSS symptom of FEP in a Chinese Han population.","PeriodicalId":520641,"journal":{"name":"Human psychopharmacology","volume":" ","pages":"274-9"},"PeriodicalIF":1.7,"publicationDate":"2014-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/hup.2396","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40299080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13

Cardiovascular pharmacodynamics of donepezil hydrochloride on the PR and QT intervals in patients with dementia. 盐酸多奈哌齐对痴呆患者PR和QT间期的心血管药效学影响。

IF 1.7

Human psychopharmacology Pub Date : 2014-05-01 Epub Date: 2014-03-11 DOI: 10.1002/hup.2398

Hirofumi Igeta, Yutaro Suzuki, Misuzu Tajiri, Toshiyuki Someya

{"title":"Cardiovascular pharmacodynamics of donepezil hydrochloride on the PR and QT intervals in patients with dementia.","authors":"Hirofumi Igeta, Yutaro Suzuki, Misuzu Tajiri, Toshiyuki Someya","doi":"10.1002/hup.2398","DOIUrl":"https://doi.org/10.1002/hup.2398","url":null,"abstract":"Objective: Although several case reports suggested that donepezil hydrochloride can induce bradycardia or atrioventricular block, the details remain unclear. We implemented a study of the impact of donepezil hydrochloride administration on PR, RR, and QT intervals.Methods: The subjects were 18 patients who were diagnosed with either dementia or cognitive disorder (DSM-IV-TR) and were hospitalized between January 2011 and December 2012. After hospitalization, they were treated with donepezil hydrochloride. Clinical parameters and electrocardiograms before and after the administration of donepezil hydrochloride were retrieved from the patients' medical records.Results: After the administration of donepezil hydrochloride, the mean PR interval significantly increased from 177.3 ± 30.9 to 186.8 ± 38.4 ms (p<0.001). And the mean RR interval also significantly increased from 850.3 ± 112.5 to 886.7 ± 136.4 ms (p=0.014). The mean difference in the PR interval before and after the administration of donepezil hydrochloride was 9.5 ± 17.1 (range=-21.0-44.0) ms. The QT intervals were unaffected by the administration of donepezil hydrochloride.Conclusions: Care should be taken when administering donepezil to patients with atrioventricular block, or patients taking other drugs that can prolong the PR interval. Copyright © 2014 John Wiley & Sons, Ltd.","PeriodicalId":520641,"journal":{"name":"Human psychopharmacology","volume":" ","pages":"292-4"},"PeriodicalIF":1.7,"publicationDate":"2014-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/hup.2398","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40299486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 12

Positive perception of pharmacogenetic testing for psychotropic medications. 对精神药物药物遗传学检测的积极看法。

IF 1.7

Human psychopharmacology Pub Date : 2014-05-01 Epub Date: 2014-03-07 DOI: 10.1002/hup.2383

Matthew B Lanktree, Gwyneth Zai, Laura E Vanderbeek, Daniel E Giuffra, David S Smithson, Lucas B Kipp, Timothy R Dalseg, Mark Speechley, James L Kennedy

{"title":"Positive perception of pharmacogenetic testing for psychotropic medications.","authors":"Matthew B Lanktree, Gwyneth Zai, Laura E Vanderbeek, Daniel E Giuffra, David S Smithson, Lucas B Kipp, Timothy R Dalseg, Mark Speechley, James L Kennedy","doi":"10.1002/hup.2383","DOIUrl":"https://doi.org/10.1002/hup.2383","url":null,"abstract":"Introduction: Pharmacogenetics attempts to identify inter-individual genetic differences that are predictive of variable drug response and propensity to side effects, with the prospect of assisting physicians to select the most appropriate drug and dosage for treatment. However, many concerns regarding genetic tests exist. We sought to test the opinions of undergraduate science and medical students in southern Ontario universities toward pharmacogenetic testing.Methods and results: Questionnaires were completed by 910 undergraduate medicine and science students from 2005 to 2007. Despite students' concerns that the results of genetic tests may be used for other purposes without consent (71%) or lead to discrimination (78%), an overwhelming number of students were in favor of pharmacogenetic testing (90%).Discussion: To our knowledge, this study is the first to survey a large sample for their attitude toward pharmacogenetic testing for psychotropic medications. Our results indicate that, although concerns remain and scientific advancements are required, respondents were in support of pharmacogenetic testing for medications used to treat schizophrenia. © 2014 The Authors. Human Psychopharmacology: Clinical and Experimental published by John Wiley & Sons, Ltd.","PeriodicalId":520641,"journal":{"name":"Human psychopharmacology","volume":" ","pages":"287-91"},"PeriodicalIF":1.7,"publicationDate":"2014-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/hup.2383","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40289737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 24

Association of ADRA2A and MTHFR gene polymorphisms with weight loss following antipsychotic switching to aripiprazole or ziprasidone. ADRA2A和MTHFR基因多态性与改用阿立哌唑或齐拉西酮后体重减轻的关系

IF 1.7

Human psychopharmacology Pub Date : 2014-01-01 Epub Date: 2013-11-25 DOI: 10.1002/hup.2366

Siti Norsyuhada Roffeei, Gavin P Reynolds, Nor Zuraida Zainal, Mas Ayu Said, Ahmad Hatim, Syarinaz Ahmad Aida, Zahurin Mohamed

{"title":"Association of ADRA2A and MTHFR gene polymorphisms with weight loss following antipsychotic switching to aripiprazole or ziprasidone.","authors":"Siti Norsyuhada Roffeei, Gavin P Reynolds, Nor Zuraida Zainal, Mas Ayu Said, Ahmad Hatim, Syarinaz Ahmad Aida, Zahurin Mohamed","doi":"10.1002/hup.2366","DOIUrl":"https://doi.org/10.1002/hup.2366","url":null,"abstract":"Objectives: Various genetic polymorphisms have been reported to be associated with antipsychotic-induced weight gain. In this study, we aimed to determine whether risk polymorphisms in 12 candidate genes are associated with reduction in body mass index (BMI) of patients following switching of antipsychotics to aripiprazole or ziprasidone.Methods: We recruited 115 schizophrenia patients with metabolic abnormalities and who have been on at least 1 year treatment with other antipsychotics; they were then switched to either aripiprazole or ziprasidone. They were genotyped, and their BMI monitored for 6 months.Results: Significant associations with reduction in BMI at 6 months following switching were found in two of these genes: with rs1800544 of the ADRA2A gene (CC + CG [-0.32 ± 1.41 kg/m²] vs GG [-1.04 ± 1.63 kg/m²], p = 0.013) and with rs1801131 of the MTHFR gene (AA [-0.36 ± 1.53] vs AC + CC [-1.07 ± 1.53], p = 0.015).Conclusion: The study data indicated that carriage of the ADRA2A rs1800544 GG genotype and the MTHFR rs1801131 C allele are associated with BMI reduction in this population following switching of antipsychotics to aripiprazole and ziprasidone.","PeriodicalId":520641,"journal":{"name":"Human psychopharmacology","volume":" ","pages":"38-45"},"PeriodicalIF":1.7,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/hup.2366","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32030845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13

Does omega-3 fatty acid supplementation enhance neural efficiency? A review of the literature. 补充omega-3脂肪酸能提高神经效率吗?文献综述。

IF 1.7

Human psychopharmacology Pub Date : 2014-01-01 DOI: 10.1002/hup.2370

Isabelle Bauer, Sheila Crewther, Andrew Pipingas, Laura Sellick, David Crewther

{"title":"Does omega-3 fatty acid supplementation enhance neural efficiency? A review of the literature.","authors":"Isabelle Bauer, Sheila Crewther, Andrew Pipingas, Laura Sellick, David Crewther","doi":"10.1002/hup.2370","DOIUrl":"https://doi.org/10.1002/hup.2370","url":null,"abstract":"Objective: While the cardiovascular, anti-inflammatory and mood benefits of omega-3 supplementation containing long chain fatty acids (LCPUFAs) such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) are manifest, there is no scientific consensus regarding their effects on neurocognitive functioning. This review aimed to examine the current literature on LCPUFAs by assessing their effects on cognition, neural functioning and metabolic activity. In order to view these findings together, the principle of neural efficiency as established by Richard Haier (\"smart brains work less hard\") was extended to apply to the neurocognitive effects of omega-3 supplementation.Methods: We reviewed multiple databases from 2000 up till 2013 using a systematic approach and focused our search to papers employing both neurophysiological techniques and cognitive measures.Results: Eight studies satisfied the criteria for consideration. We established that studies using brain imaging techniques show consistent changes in neurochemical substances, brain electrical activity, cerebral metabolic activity and brain oxygenation following omega-3 supplementation.Conclusions: We conclude that, where comparison is available, an increase in EPA intake is more advantageous than DHA in reducing \"brain effort\" relative to cognitive performance.","PeriodicalId":520641,"journal":{"name":"Human psychopharmacology","volume":" ","pages":"8-18"},"PeriodicalIF":1.7,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/hup.2370","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31909678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 23

Effects of central nervous system drugs on driving: speed variability versus standard deviation of lateral position as outcome measure of the on-the-road driving test. 中枢神经系统药物对驾驶的影响:速度变异性与横向位置标准偏差作为道路驾驶考试的结果测量。

IF 1.7

Human psychopharmacology Pub Date : 2014-01-01 DOI: 10.1002/hup.2377

Joris C Verster, Thomas Roth

{"title":"Effects of central nervous system drugs on driving: speed variability versus standard deviation of lateral position as outcome measure of the on-the-road driving test.","authors":"Joris C Verster, Thomas Roth","doi":"10.1002/hup.2377","DOIUrl":"https://doi.org/10.1002/hup.2377","url":null,"abstract":"Background: The on-the-road driving test in normal traffic is used to examine the impact of drugs on driving performance. This paper compares the sensitivity of standard deviation of lateral position (SDLP) and SD speed in detecting driving impairment.Methods: A literature search was conducted to identify studies applying the on-the-road driving test, examining the effects of anxiolytics, antidepressants, antihistamines, and hypnotics. The proportion of comparisons (treatment versus placebo) where a significant impairment was detected with SDLP and SD speed was compared.Results: About 40% of 53 relevant papers did not report data on SD speed and/or SDLP. After placebo administration, the correlation between SDLP and SD speed was significant but did not explain much variance (r = 0.253, p = 0.0001). A significant correlation was found between ΔSDLP and ΔSD speed (treatment-placebo), explaining 48% of variance. When using SDLP as outcome measure, 67 significant treatment-placebo comparisons were found. Only 17 (25.4%) were significant when SD speed was used as outcome measure. Alternatively, for five treatment-placebo comparisons, a significant difference was found for SD speed but not for SDLP.Conclusions: Standard deviation of lateral position is a more sensitive outcome measure to detect driving impairment than speed variability.","PeriodicalId":520641,"journal":{"name":"Human psychopharmacology","volume":" ","pages":"19-24"},"PeriodicalIF":1.7,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/hup.2377","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31987802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 19

A meta-analysis of inositol for depression and anxiety disorders. 肌醇治疗抑郁症和焦虑症的荟萃分析。

Human psychopharmacology Pub Date : 2014-01-01 Epub Date: 2013-12-03 DOI: 10.1002/hup.2369

Tomohiko Mukai, Taro Kishi, Yuki Matsuda, Nakao Iwata

{"title":"A meta-analysis of inositol for depression and anxiety disorders.","authors":"Tomohiko Mukai, Taro Kishi, Yuki Matsuda, Nakao Iwata","doi":"10.1002/hup.2369","DOIUrl":"10.1002/hup.2369","url":null,"abstract":"Objective: This study is a meta-analysis of inositol as a treatment for depression and anxiety disorders.Methods: PubMed, Cochrane Library database, and PsycINFO were searched up to 14 August 2013. A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials (RCTs) were conducted comparing inositol for depressed or anxiety disorder patients.Results: Seven RCTs in depression (two bipolar depression studies, one bipolar depression and major depressive disorder (MDD) study, two MDD studies, and two premenstrual dysphoric disorder (PMDD) studies) (n = 242) were identified. Four RCTs in anxiety disorders (two obsessive-compulsive disorder studies, one panic disorder study, and one posttraumatic stress disorder study) (n = 70) were also identified. There were no statistically significant effects of inositol on depressive, anxiety, and obsessive-compulsive symptoms and discontinuation (all-cause, side effects, and worsening psychiatric symptoms). However, inositol had marginally more responders in depression than placebo (p = 0.06), and inositol showed a trend towards superior efficacy for depressive symptoms in patients with PMDD (p = 0.07). Inositol marginally caused gastrointestinal upset compared with placebo (p = 0.06).Conclusions: Our results suggest that inositol may be beneficial for depressed patients, especially those with PMDD. The main limitation of this report is that a small number of studies were included in this meta-analysis.","PeriodicalId":520641,"journal":{"name":"Human psychopharmacology","volume":" ","pages":"55-63"},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32028510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0